CRVS — Corvus Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1626971 ·
Last close
$11.87
Market Cap
$998.52M
52W High
$26.95
52W Low
$6.39
ADV30
994,680
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -19,297,000 | -17,959,000 | 239,274,000 | 18,905,000 | 13,946,000 |
| Mar 2026 | 0 | — | -14,877,000 | -13,692,000 | 253,195,000 | 40,102,000 | 12,516,000 |
| Dec 2025 | 0 | — | -12,217,000 | -12,321,000 | 71,119,000 | 4,576,000 | 9,914,000 |
| Sep 2025 | 0 | — | -10,572,000 | -10,157,000 | 80,474,000 | 2,867,000 | 8,706,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-44,529,000
Investing CF
$-142,549,000
Financing CF
$191,292,000
CapEx
$-811,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.61
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-443,944,000
Inventory
—
Receivables
$1,849,000
ST Investments
$196,323,000
EBIT TTM
$-56,963,000
Pretax Income TTM
$-54,129,000
Interest Exp TTM
—
Analysts
7
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -42,971,000 | -15,283,000 | 71,119,000 | 9,914,000 | 61,205,000 | -32,797,000 |
| Dec 2024 | 0 | -27,548,000 | -62,293,000 | 68,907,000 | 36,339,000 | 32,568,000 | -25,424,000 |
| Dec 2023 | 0 | -23,407,000 | -27,029,000 | 45,553,000 | 6,869,000 | 38,684,000 | -23,935,000 |
| Dec 2022 | 0 | -32,565,000 | -41,307,000 | 68,240,000 | 12,125,000 | 56,115,000 | -27,023,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.07
Max Pain — expiry 2026-10-16
max pain strike: $12.00 · spot: $11.76 · call oi: 7,569 · put oi: 3,574
Expected Move to 2026-10-16:
±$1.47
(12.50%) —
implied range
$10.29 –
$13.23
· ATM straddle on $12.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PCRX | Pacira BioSciences, Inc. | $1.01B | $25.39 | — |
| MLTX | MoonLake Immunotherapeutics | $983.83M | $11.56 | — |
| JANX | Janux Therapeutics, Inc. | $1.01B | $16.58 | — |
| ABUS | Arbutus Biopharma Corp | $962.79M | $4.86 | — |
| AKTS | Aktis Oncology, Inc. | $1.04B | $19.35 | — |
News headlines (Yahoo Finance, 1h cache)
Corvus Pharmaceuticals (CRVS) Faces A Valuation Test, Is The Upside Already Priced In?
2026-09-25 14:09 · Yahoo
Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference
2026-09-03 12:30 · Yahoo
Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial
2026-08-27 11:30 · Yahoo
Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting
2026-08-17 15:16 · Yahoo
Corvus Pharmaceuticals (CRVS) Q2 2026 Earnings Call Transcript
2026-08-14 15:42 · Yahoo
Corvus Pharmaceuticals Inc (CRVS) (Q2 2026) Earnings Call Highlights: Advancing Soquelitinib ...
2026-08-07 05:09 · Yahoo
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results
2026-08-06 20:01 · Yahoo
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026
2026-07-30 20:01 · Yahoo
Corvus Pharmaceuticals Faces Key Soquelitinib Data And Possible M&A Interest
2026-06-14 22:09 · Yahoo
Is Corvus Pharmaceuticals, Inc. (CRVS) A Good Stock To Buy Now?
2026-06-13 15:53 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.